Enventric develops vascular medical devices for cerebral infarction treatment, with approved products including the EvoGlide distal access catheter and the ULTRIVA stent retriever. The company reported cumulative revenue of about 6 billion won over the past four years and a compound annual growth rate of 52.9% over that period. Enventric is accelerating R&D and expanding manufacturing capacity following recent regulatory approvals. It is pursuing global market entry and has begun formal IPO preparations on KOSDAQ, appointing Kiwoom Securities as its underwriter. The recent 34.5 billion won pre-IPO equity raise broadens its institutional investor base and includes follow-on participation from several existing investors. Management has stated the capital will be used to bolster R&D, scale manufacturing, and support the company’s listing and international expansion efforts.

Total raised

$23M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026